Fluoroquinolones

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 3, 2001, Pages 211-223

  Cross Jr , J Thomas ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HEADACHE; HUMAN; INFECTION; META ANALYSIS; NAUSEA; PNEUMONIA; PROSTATITIS; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; SEXUALLY TRANSMITTED DISEASE; URINARY TRACT INFECTION; VOMITING; WOUND INFECTION;

EID: 0034933892     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.24096     Document Type: Article

References (112)

1. Effects on growth of single short courses of fluoroquinolones
2. Ciprofloxacin in pediatrics, worldwide clinical experience based on compassionate use-safety report
3. Use of fluoroquinolones in pediatrics: Consensus report of an international society of chemotherapy commission
4. Tolerance and safety of ciprofloxacin in pediatric patients
5. Fluoroquinolones in pediatrics
6. Safety and tolerability of fluoroquinolones
7. Major advances in antibacterial quinolone therapy
8. 1,8-Naphthridine derivatives: A new class of chemotherapeutic agents
9. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids
10. New structure-activity relationships of the quinolone antibacterials using the target enzyme: The development and application of a DNA gyrase assay
11. Recent developments in the field of quinolone antibacterial agents
12. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro
13. Ofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
14. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects
15. Structure-activity relationships of the quinolone antibacterials: The nature of the C-7 side chain
16. Molecular effects of 4-quinolones upon DNA gyrase: DNA systems
17. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus
18. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
19. Quinolone antibacterial agents: Synthesis and structure-activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthridine-3-carboxylic acids
20. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones
21. Pharmacokinetics of gyrase inhibitors, part I: Basic chemistry and gastrointestinal disposition
22. The physicochemical properties of quinolone antimicrobials variously substituted at C-7. Implications in the development of liquid dosing forms
23. Type II DNA topoisomerases as antibacterial targets
24. DNA gyrase topoisomerase IV, and the 4-quinolones
25. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
26. DNA topoisomerases
27. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance
28. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli
29. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex
30. Mechanisms of action and resistance of older and newer fluoroquinolones
31. Quinolone resistance mutations in topoisomerase IV: Relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus
32. Mechanisms of quinolone resistance
33. Primary targets of fluoroquinolones in Streptococcus pneumoniae
34. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
35. Efflux mediated fluoroquinolone resistance in Staphylococcus aureus
36. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
37. Pharmacokinetics a of ciprofloxacin in pediatric cystic fibrosis patients
38. Single dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children
39. Pharmacokinetics of single dose oral ciprofloxacin in infants and small children
40. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae
41. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
42. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 Results from the SENTRY antimicrobial surveillance program
43. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander project 1992-1996
44. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program
45. Importance of atypical pathogens of community-acquired pneumonia
46. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: Analysis of results from the SENTRY antimicrobial surveillance program (1997)
47. Comparative in-vitro activities of five fluoroquinolones against mycobacteria
48. Comparative in-vitro activity of sparfloxacin against genital pathogens
49. A multicenter comparative trial of three-day norfloxacin vs. ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections
50. Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women
51. Oral antibiotic therapy for acute pyelonephritis. A methodological review of the literature
52. Ciprofloxacin and co-trimox azole in urinary tract infection
53. Norfloxacin treatment in uncomplicated urinary tract infection
54. Chronic bacterial prostatitis: Therapeutic experience with ciprofloxacin
55. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men
56. Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase producing and non-penicillinase producing Neisseria gonorrhoeae strains
57. Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women
58. Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhoea in men
59. Treatment of adult gonococcal keratoconjunctivitis with oral norfloxacin
60. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis
61. 1998 Sexually transmitted diseases treatment guidelines
62. Sequential intravenous-oral administration of ciprofloxacin vs. ceftazidime in serious bacterial respiratory tract infections
63. Ofloxacin in lower respiratory tract infections
64. Practice guidelines for the management of community-acquired pneumonia in adults
65. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
66. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis
67. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections
68. Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin
69. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: Evidence of satisfactory penetration into the cerebrospinal fluid
70. Neonatal Salmonella meningitis: Two case reports
71. Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis
72. A randomized controlled trial of oral or intravenous trovafloxacin versus ceftriaxone in the treatment of epidemic meningococcal meningitis
73. Osteomyelitis
74. Salmonella septic arthritis: Additional 2 cases with quinolone treatment
75. Arthrite septique a Pasteurella multocida. Traitement par une fluoroquinolone
76. Adverse reactions to fluoroquinolones in adults and children
77. Overview of fluoroquinolone safety
78. Reduced enteral absorption of ciprofloxacin in the presence of antacids
79. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin
80. Inhibition of norfloxacin absorption by antacids
81. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers
82. Effect of sucralfate on absorption of norfloxacin and ofloxacin
83. Milk and yogurt do not impair the absorption of ofloxacin
84. Interference of dairy products with the absorption of ciprofloxacin
85. The influence of quinolone derivatives on theophylline clearance
86. Enoxacin-warfarin interaction: Pharmacokinetic and sterochemical aspects
87. Ciprofloxacin does not impair the elimination of diazepam in humans
88. Co-administration of ciprofloxacin and cyclosporine: Lack of evidence for pharmacokinetic interaction
89. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals
90. Overview of toxicological studies
91. Role of the new quinolones in pediatric practice
92. Ciprofloxacin inhibition of experimental fracture-healing
93. Magnetic resonance imaging in children receiving quinolones: No evidence of quinolone-induced arthropathy
94. Safety of ciprofloxacin therapy in children: Magnetic resonance images, body fluid levels of fluoride and linear growth
95. Clinical, radiologic, and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin
96. Safety and efficacy of ciprofloxacin in pediatric patients -Review
97. Oral ciprofloxacin in the treatment of Pseudomonas exacerbations of paediatric cystic fibrosis: Clinical efficacy and safety evaluation using magnetic resonance image scanning
98. Morphological studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients
99. Fluoroquinolones in the treatment of cystic fibrosis
100. Sequential ciprofloxacin in pediatric cystic fibrosis: Comparative studies vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
101. Treatment with ciprofloxacin in children with typhoid fever
102. Effects on growth of single short courses of fluoroquinolones
103. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis
104. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: Report of 12 cases and review
105. Ciprofloxacin for treatment of tularemia in children
106. Streptomycin and alternative agents for the treatment of tularemia: Review of the literature
107. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer
108. Ciprofloxacin as a therapeutic modality in pediatric burn wound infections
109. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)
110. Safety of new quinolone in pregnancy
111. Pregnancy outcome following gestational exposure to fluoroquinolones: A multicenter prospective controlled study
112. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children